Animals ; Carcinoma, Hepatocellular ; genetics ; therapy ; Genetic Therapy ; methods ; Humans ; Liver Neoplasms, Experimental ; genetics ; therapy ; Treatment Outcome

OBJECTIVESTo evaluate the efficacy of recombinant human adenovirus p53 gene therapy (rAd-p53) in the rabbit VX2 liver cancer model using different interventional therapy approach.

METHODSThirty New Zealand rabbits implanted with VX2 tumor in the liver were randomized into five groups with six of each. The tumor volumes (V1) were measured by MRI and CT scan 11 days after tumors implanted. The interventional therapy scheme performed as below: intraarterial 0.9% saline solution perfusion in group A, transcatheter arterial embolization with 0.5 ml ultrafluid lipiodol in group B, intraarterial rAd-p53 gene perfusion in group C (1 x 10(6)/VP); intraarterial rAd-p53 gene perfusion (1 x 10(6)/VP) in combination with transcatheter arterial embolization (ultrofluid lipiodol, 0.5 ml) in group D and intratumoral rAd-p53 gene (1 x 10(6)/VP) injection in group E. The tumor volumes (V2) were measured by MRI and CT scan, and the tumor growth ratios were calculated 14 days after interventional procedures. Then all animals were sacrificed.

RESULTSThe tumor tissues were explanted for immunohistochemistry to observe the expressions of vascular endothelial cell growth factor (VEGF) and factor VIII. Microvessel density (MVD) of the tumor tissues was assessed by factor VIII immunohistochemical analysis. In addition, apoptotic index was assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. The tumor volumes before therapy were (79.4+/-8.2), (75.3+/-7.8), (74.6+/-6.6), (78.7+/-9.1), (75.8+/-8.4) mm(3) respectively, without differences found among them (F = 12.248, P = 0.0636). But the tumor volumes after therapy were (564.7+/-96.7), (176.5+/-83.2), (239.6+/-42.8), (159.8+/-58.6), (334.7+/-32.6) mm(3) respectively (F = 24.537, P = 0.0218). The tumor growth ratios were 6.9, 2.6, 3.1, 1.6 and 4.1 respectively. The mean apoptosis index were 12.0%+/-1.1%, 14.5%+/-2.1%, 17.6%+/-2.3%, 18.6%+/-2.3% and 19.6%+/-2.5% respectively. with significant differences in group E in comparison with the other four groups. Mean positive ratio of VEGF was 50.0%, 83.3%, 83.3%, 50.0% and 50.0% respectively, with significant differences observed in group B and group C compared with the other three groups (F = 7.84, P = 0.019). The differences of VIII factor positive expression ratio among each group were significant (F = 0.854, P = 0.018). Statistical analysis showed a positive correlation between the expression of VEGF and MVD (r = 2.400, P = 0.0233).

CONCLUSIONThe rAd-p53 has effective treatment outcomes in VX2 rabbit liver cancer, and intra-arterial rAd-p53 gene perfusion in combination with transcatheter arterial embolization is the best approach in comparison with intra-arterial rAd-p53 gene perfusion, transcatheter arterial embolization and intratumoral rAd-p53 gene injection alone.

Adenoviruses, Human ; genetics ; Animals ; Genes, p53 ; Genetic Therapy ; Liver Neoplasms, Experimental ; pathology ; therapy ; Rabbits ; Treatment Outcome

OBJECTIVETo construct and express secretive endostatin eukaryotic plasmid for treatment of hepatoma.

METHODSMouse Igk signal peptide sequence was synthesized and cloned into pcDNA3.1 with endostatin gene. The supernant of BHK-21 transfected with recombinant was used to culture ECV304. The proliferation of latter was evaluated by MTT assay. H22 was inoculated intramusclely, then naked DNA of endostatin plasmid was injected into the inoculation site. Tumors were dissected and weighted after treatments. All data was analyzed by SPSS10.0.

RESULTSThe supernant of BHK-21 transfected with recombinant can inhibit the proliferation of ECV304 by 29.2%. Tumor weight lighter after injected with naked pSecES (1.34 g+/-0.96g) compared with naked pcDNA3.1 (2.70g+/-0.82g) and saline (3.73g+/-1.41g).

CONCLUSIONThe endostatin eukaryotic plasmid was constructed and it can be used for gene therapy on hepatoma.

Animals ; Endostatins ; genetics ; secretion ; Genetic Therapy ; Liver Neoplasms, Experimental ; therapy ; Male ; Mice ; Plasmids

*Chemoembolization, Therapeutic/methods ; Drugs, Chinese Herbal/*administration & dosage ; Hepatic Artery ; Liver Neoplasms, Experimental/pathology ; Liver Neoplasms, Experimental/*therapy ; Orchidaceae ; Phytotherapy ; Rats, Inbred ACI

OBJECTIVETo observe effects of cold- and hot-property herbs and effects of hot and cold constitutions on the tumor growth of tumor bearing rats, and to observe the effect of Cinobufacini Injection (CI) on the tumor growth of tumor bearing rats of different constitutions.

METHODSEighty healthy male Wistar rats were randomly divided into eight groups, i.e., the tumor bearing control group, the tumor bearing heat syndrome group, the tumor bearing cold syndrome group, the heat syndrome tumor bearing group, the cold syndrome tumor bearing group, the tumor bearing CI group, the heat syndrome tumor bearing CI group, and the cold syndrome tumor bearing CI group, respectively. The weight and volume of rats' subcutaneous tumor were measured 14 days after tumor inoculation.

RESULTSThe weight and volume of tumor in the heat syndrome tumor bearing CI group [(3.55 +/- 1.12) g, (2864.44 +/- 1430.51) mm3] and the tumor bearing CI group [(4.29 +/- 1.14) g, (3397.19 +/- 1701.13) mm3] were significantly lower than those of the tumor bearing control group [(6.01 +/- 2.45) g, (6218.91 +/- 3837.64) mm3] and the cold syndrome tumor bearing CI group [(6.90 +/- 1.57) g, (6168.42 +/- 2457.03) mm3], showing statistical difference (P<0.05). There was insignificant difference among other groups.

CONCLUSIONSCI showed better tumor inhibition effects on tumor bearing rats of heat syndrome constitution, which indicated CI was of cold property. It might be possibly used in tumor bearing rats of heat syndrome constitution.

Animals ; Bufanolides ; pharmacology ; therapeutic use ; Injections ; Male ; Neoplasms, Experimental ; drug therapy ; pathology ; Rats ; Rats, Wistar

Radio frequency ablation has become a valuable method in treating cancers or tumors for its wide adaptability, better efficacy, convenience and safety. This paper introduces the research and development of a multipolar RF tumor therapy system based on the technology of destroying hypoxic cell. This is an intellectualized tumor curing system.
Animals ; Catheter Ablation ; instrumentation ; methods ; Electrodes ; Equipment Design ; Mice ; Mice, Nude ; Neoplasms, Experimental ; therapy ; Software Design

*Chemoembolization, Therapeutic ; Liver Neoplasms, Experimental/*therapy ; Microspheres ; Polyglactin 910/*therapeutic use ; Rats, Inbred ACI

The microencapsulated genetic cells may be a new platform instead of genetic engineering drugs, as they can overcome the genetic engineering drugs' shortages such as short half-life in vivo, low activity, and incomplete elimination of organic solvent. This article reviews and summarizes the advantages, possible problems and solution and the feasibility of using microencapsulated genetic engineering cells in the treatment of cancer.
Animals ; Capsules ; Cell Transplantation ; Combined Modality Therapy ; Drug Compounding ; methods ; Genetic Engineering ; Genetic Therapy ; methods ; Mice ; Neoplasms, Experimental ; therapy ; Transfection

Animals ; Carcinoma in Situ ; therapy ; Cell Line, Tumor ; Genetic Therapy ; methods ; Interleukin-12 ; genetics ; Liver Neoplasms, Experimental ; therapy ; Mice ; Neoplasm Transplantation

Animals ; Combined Modality Therapy ; Endostatins ; genetics ; Genetic Therapy ; Liver Neoplasms, Experimental ; radiotherapy ; therapy ; Mice ; Mice, Nude ; Neoplasm Transplantation